We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Fremanezumab in Participants With Posttraumatic Headache (PTH)

- Post-Traumatic Headache
- Completed

Study Title: A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)

Teva Identifier: TV48125-CNS-20024

ClinicalTrials.gov Identifier: NCT03347188

Study Status: Completed

Trial Condition(s): Post-Traumatic Headache

Interventions: Drug: Fremanezumab | Drug: Placebo

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years to 70 Years

Trial Duration: November 17, 2017 - June 3, 2020

Phase: Phase 2

Study Type

Interventional